



## **EGF THERAMED HEALTH CORP. CLOSES PRIVATE PLACEMENT OF \$1,430,000**

**Vancouver, B.C., April 22, 2020** – EGF THERAMED HEALTH CORP. (CSE: TMED, OTCQB: EVAHF) (the “Company”)

EGF Theramed Health Corp. has closed its previously announced (dated April 13, 2020) non-brokered private placement.

The Company has closed on 2,860,000 units at a price of \$0.50 per unit for gross proceeds of \$1,430,000. Each unit consists of one common share and one common share purchase warrant, with each warrant entitling the holder to acquire an additional common share of the Company at a price of \$0.75 for a period of 18 months from the closing of the offering.

In connection with the private placement, the Company has paid cash finders’ fee of \$29,100 and issued 57,000 finder’s warrants at an exercise price of \$0.75 expiring 18 months from the date of issue. All securities issued in the offering are subject to a hold period expiring on August 23, 2020.

The net proceeds from the non-brokered private placement are intended to be used for working capital and acquisitions.

The company has increased its efforts in researching psilocybin and psychedelic extraction and processing for its world-class Las Vegas extraction lab. Specifically, the company is looking into Psilocybin micro-dosing, which, has effects of reducing stress, anxiety and pain without many of the side effects associated with traditional pharmacology products.

“We are evaluating multiple projects that we feel have considerable upside potential that go hand in hand with our existing assets. Both CBD and Psilocybin carry unique and undeniable health benefits,” states David Bentil.

For more information please contact:

### **EGF THERAMED HEALTH CORP.**

Contact: David Bentil, CEO

Email [theramedhealthcorp@gmail.com](mailto:theramedhealthcorp@gmail.com)

Telephone: (778) 559-3939

Website <http://www.theramedhealthcorp.com>

CSE Micro-site: <http://thecse.com/en/listings/technology/Theramed-Health-Corporation>

US OTC Markets (OTCQB): <http://www.otcmarkets.com/stock/EVAHF/news>

**About EGF THERAMED HEALTH CORP. (CSE: TMED, OTCQB: EVAHF)**

EGF Theramed Health Corp. is a technology company focused in the healthcare and life sciences sector to develop a personalized healthcare system. The company through its subsidiaries has assets and technologies involved in extracting and purifying botanical extracts, creating formulations, and with its medical device technology monitoring capabilities. EGF Theramed's unique combination of technologies may allow it to be the first to be able to offer a complete quality assured vertically integrated "Natural Products and Herbal Health System" for monitoring, dosing, and recording the effects of natural products on your cardiovascular system.

**DISCLAIMERS**

This news release contains forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company's Management's Discussion and Analysis and other disclosure filings with Canadian securities regulators and on the OTC Markets website which is posted on [www.sedar.com](http://www.sedar.com), <https://thecse.com/en/listings/technology/egf-theramed-health-corp>, and <http://www.otcmarkets.com/stock/EVAHF/filings>. This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE), or any other regulatory authority accepts responsibility for the adequacy or accuracy of this release. The Company does not undertake to update this news release unless required by applicable law.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities law and may not be offered or sold in the "United States", as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.